TB Research

A clinician's guide to managing multidrug-resistant tuberculosis in children and adolescents

Burkhardt I, Götzinger F, Iipumbu L, Whittaker E, Günther G, Seddon JA

Expert review of respiratory medicine · 2025-11

Abstract

Introduction A small fraction of the estimated 25,000-30000 children ( Areas covered We present current data on pediatric and adolescent MDR-TB combined with expert opinion to guide the reader through the pediatric and adolescent MDR-TB care cascade. This includes background information and practical guidance on the disease, the epidemiology, diagnostics, treatment options, and post MDR-TB sequalae. We also address the special circumstances of adolescents, comorbidities, and the socioeconomic impact of MDR-TB. PubMed was searched for suitable articles and national and international guidelines were reviewed. Expert opinion The roll-out of low complexity molecular diagnostics and advanced techniques, such as targeted next-generation sequencing, have the potential to rapidly diagnose children and adolescents with MDR-TB. The recently introduced short-all oral regimens provide safer and shorter treatment options. The effectiveness of levofloxacin as MDR-TB preventive treatment has been demonstrated. However, wide implementation of such new and advanced tools is still pending and improvements in diagnostics are crucial to increasing the proportion of children and adolescents with MDR-TB being diagnosed.

MeSH terms

  • Humans
  • Mycobacterium tuberculosis
  • Tuberculosis, Multidrug-Resistant
  • Antitubercular Agents
  • Treatment Outcome
  • Adolescent
  • Child
  • Practice Guidelines as Topic